Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

Exclusion Criteria

• •1. Females who have passed menarche at screening
• •2. Concomitant skin diseases that may confound AD assessments in the opinion of the investigator
• •3. Has a known medical issue which may contribute to shorter stature (eg, growth hormone deficiency, Celiac disease)
• •4. Active helminthic infections; suspected or high risk of helminthic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before baseline
• •5. Has a known allergy or hypersensitivity to components of the study intervention
• •6. Prior use of dupilumab or other biologic treatment for AD, as defined in the protocol
• •7. Other advanced systemic treatment for AD within 4 weeks or non-steroidal topical treatments within 2 weeks before the baseline visit